VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and productivity of its proprietary ...

Cell and gene therapies offer potential new therapeutics but are currently constrained by complex and inefficient manufacturing strategies.

Even after the pandemic, various new infectious diseases continue to emerge, posing ongoing viral threats that demand robust ...

May 2025 - eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, has entered into a strategic partnership with KU Leuven, one of Europe’s leading academic ...

ReiThera, the Italian CDMO company specialized in the development and manufacturing of genetic vaccines and advanced therapies, is pleased to announce its participation in the 27th Annual Meeting of ...

Nasal Spray H5N1 Avian Influenza Vaccine Developed Apr. 8, 2025 — Scientists have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 avian ...

Collectively, the data from in vitro and in vivo studies using FUS, TDP-43, and C9orf72 models demonstrate that hUPF1 holds significant potential for treating the majority of patients with ALS and ...

Xmoor Pharma has entered into a strategic partnership with KU Leuven to support a new cell and gene therapy hub.

AnelloBricks is a promising in vitro approach to producing a new class of functional viral vectors, offering dramatic advantages in manufacturing scalability and cost compared to ...

Gene therapy developed and delivered in 10 months for child with IRF2BPL mutation; first treatment administered at Weill ...

Tozaro, an emerging technology provider in the field of cell and gene therapy manufacturing, announces the formation of its ...